Literature DB >> 20385685

Intranasal fentanyl for analgesia in the paediatric emergency department.

Maria Finn1, Dan Harris.   

Abstract

Intranasal opiate analgesia is the first choice in children presenting to paediatric emergency departments with severe pain. A prospective observational study was performed which showed that intranasal fentanyl is a safe effective alternative to diamorphine.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20385685     DOI： 10.1136/emj.2008.070474

Source DB:  PubMed          Journal:  Emerg Med J        ISSN： 1472-0205            Impact factor:   2.740


  5 in total

1.  Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

Review 2.  Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

3.  Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain.

Authors:  Sebastiano Mercadante; Renato Vellucci; Arturo Cuomo; Claudio Adile; Andrea Cortegiani; Alessandro Valle; Patrizia Villari; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2014-10-29       Impact factor: 3.603

4.  [Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management].

Authors:  B Messerer; G Grögl; W Stromer; W Jaksch
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

5.  Intranasal fentanyl versus intravenous morphine in the emergency department treatment of severe painful sickle cell crises in children: study protocol for a randomised controlled trial.

Authors:  Michael Joseph Barrett; John Cronin; Adrian Murphy; Siobhan McCoy; John Hayden; SinéadNic an Fhailí; Tim Grant; Abel Wakai; Corrina McMahon; Sean Walsh; Ronan O'Sullivan
Journal:  Trials       Date:  2012-05-30       Impact factor: 2.279
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.